

Pere GinÀ's

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9411031/publications.pdf>

Version: 2024-02-01

390
papers

50,789
citations

944

115
h-index

1668

214
g-index

421
all docs

421
docs citations

421
times ranked

18377
citing authors

#	ARTICLE	IF	CITATIONS
1	Renal Replacement Therapy for Acute Kidney Injury in Severe Alcohol-Associated Hepatitis as a Bridge to Transplant or Recovery. <i>Digestive Diseases and Sciences</i> , 2022, 67, 697-707.	1.1	7
2	Population screening for liver fibrosis: Toward early diagnosis and intervention for chronic liver diseases. <i>Hepatology</i> , 2022, 75, 219-228.	3.6	107
3	Ductular reaction promotes intrahepatic angiogenesis through Slit2â€Roundabout 1 signaling. <i>Hepatology</i> , 2022, 75, 353-368.	3.6	20
4	Urinary L-FABP is a promising prognostic biomarker of ACLF and mortality in patients with decompensated cirrhosis. <i>Journal of Hepatology</i> , 2022, 76, 107-114.	1.8	21
5	Global burden of disease: acute-on-chronic liver failure, a systematic review and meta-analysis. <i>Gut</i> , 2022, 71, 148-155.	6.1	98
6	Decompensation in Advanced Nonalcoholic Fatty Liver Disease May Occur at Lower Hepatic Venous Pressure Gradient Levels Than in Patients With Viral Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2276-2286.e6.	2.4	42
7	The EASLâ€Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality. <i>Lancet, The</i> , 2022, 399, 61-116.	6.3	257
8	Improving Outcome Prediction in Alcohol-Associated Hepatitis: Blood Urea Nitrogen and Albumin Help. <i>Mayo Clinic Proceedings</i> , 2022, 97, 436-438.	1.4	2
9	Molecular characterization of chronic liver disease dynamics: From liver fibrosis to acute-on-chronic liver failure. <i>JHEP Reports</i> , 2022, 4, 100482.	2.6	14
10	Stigmatization is common in patients with non-alcoholic fatty liver disease and correlates with quality of life. <i>PLoS ONE</i> , 2022, 17, e0265153.	1.1	18
11	Treatment With Simvastatin and Rifaximin Restores the Plasma Metabolomic Profile in Patients With Decompensated Cirrhosis. <i>Hepatology Communications</i> , 2022, 6, 1100-1112.	2.0	5
12	Low Accuracy of FIB-4 and NAFLD Fibrosis Scores for Screening for Liver Fibrosis in the Population. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2567-2576.e6.	2.4	80
13	Patterns of kidney dysfunction in acuteâ€onâ€chronic liver failure: Relationship with kidney and patientsâ€™ outcome. <i>Hepatology Communications</i> , 2022, 6, 2121-2131.	2.0	8
14	Long-term albumin treatment in patients with cirrhosis and ascites. <i>Journal of Hepatology</i> , 2022, 76, 1306-1317.	1.8	16
15	EASL International Recognition Award Recipient 2022: Prof. Patrick S. Kamath. <i>Journal of Hepatology</i> , 2022, , .	1.8	0
16	Circulating Extracellular Vesicles Carrying Sphingolipid Cargo for the Diagnosis and Dynamic Risk Profiling of Alcoholic Hepatitis. <i>Hepatology</i> , 2021, 73, 571-585.	3.6	56
17	Improved prediction of mortality by combinations of inflammatory markers and standard clinical scores in patients with acuteâ€onâ€chronic liver failure and acute decompensation. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 240-248.	1.4	11
18	Alterations in Gut Microbiome in Cirrhosis as Assessed by Quantitative Metagenomics: Relationship With Acute-on-Chronic Liver Failure and Prognosis. <i>Gastroenterology</i> , 2021, 160, 206-218.e13.	0.6	89

#	ARTICLE	IF	CITATIONS
19	Programmed Death Ligand 1 Is Overexpressed in Liver Macrophages in Chronic Liver Diseases, and Its Blockade Improves the Antibacterial Activity Against Infections. <i>Hepatology</i> , 2021, 74, 296-311.	3.6	21
20	PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis. <i>Journal of Hepatology</i> , 2021, 74, 1097-1108.	1.8	149
21	Endpoints and design of clinical trials in patients with decompensated cirrhosis: Position paper of the LiverHope Consortium. <i>Journal of Hepatology</i> , 2021, 74, 200-219.	1.8	16
22	SARS-CoV-2 vaccination in patients with liver disease: responding to the next big question. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 156-158.	3.7	49
23	Interaction between metabolic syndrome and alcohol consumption, risk factors of liver fibrosis: A population-based study. <i>Liver International</i> , 2021, 41, 1556-1564.	1.9	16
24	Profiling circulating microRNAs in patients with cirrhosis and acute-on-chronic liver failure. <i>JHEP Reports</i> , 2021, 3, 100233.	2.6	14
25	Monitoring Renal Function and Therapy of Hepatorenal Syndrome Patients with Cirrhosis. <i>Clinics in Liver Disease</i> , 2021, 25, 441-460.	1.0	2
26	Reply. <i>Gastroenterology</i> , 2021, 160, 2206.	0.6	0
27	Reply to: "Acute-on-chronic liver failure in East-Asia: an underestimated issue with limited data". <i>Gut</i> , 2021, , gutjnl-2021-324926.	6.1	0
28	Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases. <i>Hepatology</i> , 2021, 74, 1014-1048.	3.6	311
29	Hyperkalemia influences the outcome of patients with cirrhosis with acute decompensation (AD) and acute-on-chronic liver failure (ACLF). <i>Digestive and Liver Disease</i> , 2021, 53, 738-745.	0.4	5
30	Robert W Schrier, an influential observer from outside Hepatology (1936-2021). <i>Journal of Hepatology</i> , 2021, 74, 1281-1282.	1.8	0
31	The Use of Rifaximin in Patients With Cirrhosis. <i>Hepatology</i> , 2021, 74, 1660-1673.	3.6	67
32	The search for disease-modifying agents in decompensated cirrhosis: From drug repurposing to drug discovery. <i>Journal of Hepatology</i> , 2021, 75, S118-S134.	1.8	30
33	A notable proportion of liver transplant candidates with alcohol-related cirrhosis can be delisted because of clinical improvement. <i>Journal of Hepatology</i> , 2021, 75, 275-283.	1.8	23
34	Liver cirrhosis. <i>Lancet, The</i> , 2021, 398, 1359-1376.	6.3	515
35	Sequential changes in urinary biomarker levels in patients with cirrhosis and severe hepatorenal syndrome. <i>Liver International</i> , 2021, 41, 2729-2732.	1.9	6
36	...A double blind, randomised, placebo-controlled study to assess safety and tolerability of oral enterosorbent Carbalive (Yaq-001) in cirrhotic patients. , 2021, , .		5

#	ARTICLE	IF	CITATIONS
37	Editorial: microRNAs for the diagnosis of fatty liver disease in the population“are we inching closer towards the target?. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 557-558.	1.9	1
38	Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): a randomised, double-blind, placebo-controlled, phase 2 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 31-41.	3.7	75
39	Lack of evidence for a continuum between hepatorenal syndrome and acute tubular necrosis. <i>Journal of Hepatology</i> , 2020, 72, 581-582.	1.8	5
40	Are We Ready to Evaluate Adrenal Function in Patients With Decompensated Cirrhosis and Acute-on-Chronic Liver Failure?. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1040-1042.	2.4	1
41	Blood metabolomics uncovers inflammation-associated mitochondrial dysfunction as a potential mechanism underlying ACLF. <i>Journal of Hepatology</i> , 2020, 72, 688-701.	1.8	223
42	The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology. <i>Journal of Hepatology</i> , 2020, 73, 842-854.	1.8	282
43	Hepatic lipocalin 2 promotes liver fibrosis and portal hypertension. <i>Scientific Reports</i> , 2020, 10, 15558.	1.6	30
44	Hospital-Acquired Versus Community-Acquired Acute Kidney Injury in Patients With Cirrhosis: A Prospective Study. <i>American Journal of Gastroenterology</i> , 2020, 115, 1505-1512.	0.2	12
45	Hepatorenal syndrome: pathophysiology, diagnosis, and management. <i>BMJ</i> , The, 2020, 370, m2687.	3.0	116
46	Psychological Burden of Hepatic Encephalopathy on Patients and Caregivers. <i>Clinical and Translational Gastroenterology</i> , 2020, 11, e00159.	1.3	32
47	Changing epidemiology and outcomes of acute kidney injury in hospitalized patients with cirrhosis “ a US population-based study. <i>Journal of Hepatology</i> , 2020, 73, 1092-1099.	1.8	43
48	Albumin in decompensated cirrhosis: new concepts and perspectives. <i>Gut</i> , 2020, 69, 1127-1138.	6.1	190
49	Reply to: “Transition of AKI to CKD in cirrhosis” effect of baseline eGFR and unanswered questions. <i>Journal of Hepatology</i> , 2020, 73, 738-739.	1.8	0
50	Clinical Application of Kidney Biomarkers in Cirrhosis. <i>American Journal of Kidney Diseases</i> , 2020, 76, 710-719.	2.1	55
51	Chronic Kidney Disease in Cirrhosis: Emerging Complication With Negative Impact in the Liver Transplant Setting. <i>Liver Transplantation</i> , 2020, 26, 483-484.	1.3	2
52	Nursing Care of Patients With Cirrhosis: The LiverHope Nursing Project. <i>Hepatology</i> , 2020, 71, 1106-1116.	3.6	22
53	Development of chronic kidney disease after acute kidney injury in patients with cirrhosis is common and impairs clinical outcomes. <i>Journal of Hepatology</i> , 2020, 72, 1132-1139.	1.8	43
54	Statins: Old drugs as new therapy for liver diseases?. <i>Journal of Hepatology</i> , 2019, 70, 194-202.	1.8	108

#	ARTICLE	IF	CITATIONS
55	Recomendaciones para la detección, diagnóstico y seguimiento de los pacientes con enfermedad por hígado graso no alcohólico en atención primaria y hospitalaria. <i>Medicina Clínica</i> , 2019, 153, 169-177.	0.3	18
56	Editorial: evaluating cirrhosis progression—lessons from the heart. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 709-710.	1.9	1
57	Transient elastography for screening of liver fibrosis: Cost-effectiveness analysis from six prospective cohorts in Europe and Asia. <i>Journal of Hepatology</i> , 2019, 71, 1141-1151.	1.8	104
58	Recommendations for the detection, diagnosis and follow-up of patients with non-alcoholic fatty liver disease in primary and hospital care. <i>Medicina Clínica (English Edition)</i> , 2019, 153, 169-177.	0.1	7
59	Reply to: "Midodrine and albumin in decompensated cirrhosis: Down but not out". <i>Journal of Hepatology</i> , 2019, 70, 812.	1.8	0
60	Metabolomics Discloses a New Non-invasive Method for the Diagnosis and Prognosis of Patients with Alcoholic Hepatitis. <i>Annals of Hepatology</i> , 2019, 18, 144-154.	0.6	11
61	Hypervolemic Hyponatremia (Liver). <i>Frontiers of Hormone Research</i> , 2019, 52, 104-112.	1.0	7
62	Improvement of hyponatremia in cirrhosis is associated with improved complex information processing. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 1999-2003.	1.4	11
63	Addressing Profiles of Systemic Inflammation Across the Different Clinical Phenotypes of Acutely Decompensated Cirrhosis. <i>Frontiers in Immunology</i> , 2019, 10, 476.	2.2	134
64	Neutrophil Gelatinase-Associated Lipocalin for Assessment of Acute Kidney Injury in Cirrhosis: A Prospective Study. <i>Hepatology</i> , 2019, 70, 319-333.	3.6	114
65	Epidemiology and Effects of Bacterial Infections in Patients With Cirrhosis Worldwide. <i>Gastroenterology</i> , 2019, 156, 1368-1380.e10.	0.6	296
66	Prevalence and short-term mortality of acute-on-chronic liver failure: A national cohort study from the USA. <i>Journal of Hepatology</i> , 2019, 70, 639-647.	1.8	101
67	Ductular Reaction Cells Display an Inflammatory Profile and Recruit Neutrophils in Alcoholic Hepatitis. <i>Hepatology</i> , 2019, 69, 2180-2195.	3.6	52
68	Characterization of inflammatory response in hepatorenal syndrome: Relationship with kidney outcome and survival. <i>Liver International</i> , 2019, 39, 1246-1255.	1.9	64
69	Range of Normal Liver Stiffness and Factors Associated With Increased Stiffness Measurements in Apparently Healthy Individuals. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 54-64.e1.	2.4	59
70	New Strategies for the Management of Decompensated Cirrhosis: Long-Term Albumin Administration for Everyone?. <i>Hepatology</i> , 2019, 69, 2289-2291.	3.6	2
71	Multidrug-resistant bacterial infections in patients with decompensated cirrhosis and with acute-on-chronic liver failure in Europe. <i>Journal of Hepatology</i> , 2019, 70, 398-411.	1.8	225
72	Orchestration of Tryptophan-Kynurenine Pathway, Acute Decompensation, and Acute-on-Chronic Liver Failure in Cirrhosis. <i>Hepatology</i> , 2019, 69, 1686-1701.	3.6	80

#	ARTICLE	IF	CITATIONS
73	Serum sodium as a risk factor for hepatic encephalopathy in patients with cirrhosis and ascites. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 914-920.	1.4	16
74	EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. <i>Journal of Hepatology</i> , 2018, 69, 406-460.	1.8	1,762
75	High Prevalence of Liver Fibrosis Among European Adults With Unknown Liver Disease: A Population-Based Study. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1138-1145.e5.	2.4	180
76	Association Between Grade of Acute on Chronic Liver Failure and Response to Terlipressin and Albumin in Patients With Hepatorenal Syndrome. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1792-1800.e3.	2.4	127
77	More Than Meets the Eye in Using Interleukin 6 as a Marker of Inflammation and Prognostic Factor for Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 630-632.	2.4	0
78	Herbal and Dietary Supplement-Induced Liver Injuries in the Spanish DILI Registry. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1495-1502.	2.4	83
79	Cell death markers in patients with cirrhosis and acute decompensation. <i>Hepatology</i> , 2018, 67, 989-1002.	3.6	76
80	Bacterial and fungal infections in acute-on-chronic liver failure: prevalence, characteristics and impact on prognosis. <i>Gut</i> , 2018, 67, 1870-1880.	6.1	375
81	Pilot study of living donor liver transplantation for patients with hepatocellular carcinoma exceeding Milan Criteria (Barcelona Clinic Liver Cancer extended criteria). <i>Liver Transplantation</i> , 2018, 24, 369-379.	1.3	47
82	Prevalence of hepatic steatosis as assessed by controlled attenuation parameter (CAP) in subjects with metabolic risk factors in primary care. A population-based study. <i>PLoS ONE</i> , 2018, 13, e0200656.	1.1	21
83	Hepatorenal syndrome. <i>Nature Reviews Disease Primers</i> , 2018, 4, 23.	18.1	172
84	Hepatorenal syndrome in the era of acute kidney injury. <i>Liver International</i> , 2018, 38, 1891-1901.	1.9	42
85	Transient elastography for alcoholic liver disease: a step forward. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 589-591.	3.7	6
86	Midodrine and albumin for prevention of complications in patients with cirrhosis awaiting liver transplantation. A randomized placebo-controlled trial. <i>Journal of Hepatology</i> , 2018, 69, 1250-1259.	1.8	152
87	Metabolomics Discloses a New Non-invasive Method for the Diagnosis and Prognosis of Patients with Alcoholic Hepatitis. <i>Annals of Hepatology</i> , 2018, 17, 0-10.	0.6	0
88	A prospective study of the utility of plasma biomarkers to diagnose alcoholic hepatitis. <i>Hepatology</i> , 2017, 66, 555-563.	3.6	91
89	Terlipressin for hepatorenal syndrome: ready for prime time. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 75-76.	3.7	3
90	Acute-on-chronic liver failure: an update. <i>Gut</i> , 2017, 66, 541-553.	6.1	472

#	ARTICLE	IF	CITATIONS
91	Pentraxin β modulates lipopolysaccharide-induced inflammatory response and attenuates liver injury. <i>Hepatology</i> , 2017, 66, 953-968.	3.6	39
92	Short article. <i>European Journal of Gastroenterology and Hepatology</i> , 2017, 29, 535-538.	0.8	0
93	Effects of alfa β system on kidney and circulatory function in patients with cirrhosis and refractory ascites. <i>Liver Transplantation</i> , 2017, 23, 583-593.	1.3	37
94	Impact of Acute-on-Chronic Liver Failure (ACLF) on response to treatment with terlipressin and albumin in patients with type 1 hepatorenal syndrome. <i>Digestive and Liver Disease</i> , 2017, 49, e54.	0.4	3
95	Screening studies of transient elastography and FibroTest in the general population – Authors' reply. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 246-247.	3.7	0
96	Juan Rod�s In Memoriam. <i>Gastroenterology</i> , 2017, 152, 1249-1250.	0.6	0
97	Urine Interleukin 18 and Lipocalin 2 Are Biomarkers of Acute Tubular Necrosis in Patients With Cirrhosis: A Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1003-1013.e3.	2.4	67
98	Reply to: "Are we still searching for the fifth element of MELD?" <i>Journal of Hepatology</i> , 2017, 66, 247-248.	1.8	0
99	Liver injury and glatiramer acetate, an uncommon association: case report and literature review. <i>Therapeutic Advances in Neurological Disorders</i> , 2017, 10, 367-372.	1.5	9
100	Pro: Acute-on-chronic liver failure. <i>Liver Transplantation</i> , 2017, 23, 1318-1324.	1.3	3
101	Alcohol abstinence in patients surviving an episode of alcoholic hepatitis: Prediction and impact on long-term survival. <i>Hepatology</i> , 2017, 66, 1842-1853.	3.6	119
102	Adipocyte Fatty-Acid Binding Protein is Overexpressed in Cirrhosis and Correlates with Clinical Outcomes. <i>Scientific Reports</i> , 2017, 7, 1829.	1.6	30
103	Polymorphisms in the IL1 gene cluster influence systemic inflammation in patients at risk for acute-on-chronic liver failure. <i>Hepatology</i> , 2017, 65, 202-216.	3.6	39
104	Clinical course and short-term mortality of cirrhotic patients with infections other than spontaneous bacterial peritonitis. <i>Liver International</i> , 2017, 37, 385-395.	1.9	39
105	Validation of a Staging System for Acute Kidney Injury in Patients With Cirrhosis and Association With Acute-on-Chronic Liver Failure. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 438-445.e5.	2.4	125
106	Limited Efficacy of Tolvaptan in Patients with Cirrhosis and Severe Hyponatremia: Real-Life Experience. <i>American Journal of Medicine</i> , 2017, 130, 372-375.	0.6	31
107	Copeptin in acute decompensation of liver cirrhosis: relationship with acute-on-chronic liver failure and short-term survival. <i>Critical Care</i> , 2017, 21, 321.	2.5	19
108	Urine Monocyte Chemoattractant Protein-1 Is an Independent Predictive Factor of Hospital Readmission and Survival in Cirrhosis. <i>PLoS ONE</i> , 2016, 11, e0157371.	1.1	20

#	ARTICLE	IF	CITATIONS
109	Response to nosocomial spontaneous bacterial peritonitis: discussing a specific infection treatment algorithm. <i>Liver International</i> , 2016, 36, 1075-1076.	1.9	0
110	Integrative microRNA profiling in alcoholic hepatitis reveals a role for microRNA-182 in liver injury and inflammation. <i>Gut</i> , 2016, 65, 1535-1545.	6.1	103
111	LPS-TLR4 Pathway Mediates Ductular Cell Expansion in Alcoholic Hepatitis. <i>Scientific Reports</i> , 2016, 6, 35610.	1.6	25
112	Screening for liver fibrosis in the general population: a call for action. <i>The Lancet Gastroenterology and Hepatology</i> , 2016, 1, 256-260.	3.7	131
113	Acute-on-Chronic Liver Failure: The Role of Precipitating Illness. <i>Seminars in Liver Disease</i> , 2016, 36, 117-122.	1.8	22
114	Management of Hepatorenal Syndrome in the Era of Acute-on-Chronic Liver Failure: Terlipressin and Beyond. <i>Gastroenterology</i> , 2016, 150, 1525-1527.	0.6	12
115	Targeting the renin-angiotensin system in liver fibrosis. <i>Hepatology International</i> , 2016, 10, 730-732.	1.9	4
116	Systemic inflammation in decompensated cirrhosis: Characterization and role in acute-on-chronic liver failure. <i>Hepatology</i> , 2016, 64, 1249-1264.	3.6	550
117	Management of uninfected and infected ascites in cirrhosis. <i>Liver International</i> , 2016, 36, 109-115.	1.9	43
118	Plasma copeptin as biomarker of disease progression and prognosis in cirrhosis. <i>Journal of Hepatology</i> , 2016, 65, 914-920.	1.8	35
119	Acute-on-chronic liver failure in cirrhosis. <i>Nature Reviews Disease Primers</i> , 2016, 2, 16041.	18.1	320
120	Characterization of Inflammatory Response in Acute-on-Chronic Liver Failure and Relationship with Prognosis. <i>Scientific Reports</i> , 2016, 6, 32341.	1.6	101
121	Characteristics, Diagnosis and Prognosis of Acute-on-Chronic Liver Failure in Cirrhosis Associated to Hepatitis B.. <i>Scientific Reports</i> , 2016, 6, 25487.	1.6	125
122	The TLR10 polymorphism rs4129009 is associated to poor 28-day survival in patients with cirrhosis and acute on chronic liver failure precipitated by bacterial infection. <i>Digestive and Liver Disease</i> , 2016, 48, e16.	0.4	0
123	The Management of Hyponatremia in Cirrhosis: Should it Be Pharmacologic?. <i>Current Hepatology Reports</i> , 2016, 15, 53-59.	0.4	0
124	Neutrophil gelatinase-associated lipocalin is a biomarker of acute-on-chronic liver failure and prognosis in cirrhosis. <i>Journal of Hepatology</i> , 2016, 65, 57-65.	1.8	112
125	Management of the critically ill patient with cirrhosis: A multidisciplinary perspective. <i>Journal of Hepatology</i> , 2016, 64, 717-735.	1.8	243
126	Treatment with non-selective beta blockers is associated with reduced severity of systemic inflammation and improved survival of patients with acute-on-chronic liver failure. <i>Journal of Hepatology</i> , 2016, 64, 574-582.	1.8	196

#	ARTICLE	IF	CITATIONS
127	Pathogenesis of Hepatorenal Syndrome: Implications for Therapy. <i>American Journal of Kidney Diseases</i> , 2016, 67, 318-328.	2.1	74
128	Vasopressin 1a receptor partial agonism increases sodium excretion and reduces portal hypertension and ascites in cirrhotic rats. <i>Hepatology</i> , 2016, 63, 207-216.	3.6	18
129	Kinase analysis in alcoholic hepatitis identifies p90RSK as a potential mediator of liver fibrogenesis. <i>Gut</i> , 2016, 65, 840-851.	6.1	14
130	Integrative miRNA and Gene Expression Profiling Analysis of Human Quiescent Hepatic Stellate Cells. <i>Scientific Reports</i> , 2015, 5, 11549.	1.6	79
131	Treatment of type 2 hepatorenal syndrome in patients awaiting transplantation: Effects on kidney function and transplantation outcomes. <i>Liver Transplantation</i> , 2015, 21, 1347-1354.	1.3	48
132	Assessment of acute kidney injury at hospital admission in cirrhosis: estimating baseline serum creatinine is not the answer. <i>Liver International</i> , 2015, 35, 2079-2081.	1.9	4
133	Clinical Course of acute-on-chronic liver failure syndrome and effects on prognosis. <i>Hepatology</i> , 2015, 62, 243-252.	3.6	493
134	Analysis of a Urinary Biomarker Panel for Clinical Outcomes Assessment in Cirrhosis. <i>PLoS ONE</i> , 2015, 10, e0128145.	1.1	97
135	Chemokine Receptor Ccr6 Deficiency Alters Hepatic Inflammatory Cell Recruitment and Promotes Liver Inflammation and Fibrosis. <i>PLoS ONE</i> , 2015, 10, e0145147.	1.1	19
136	Systemic inflammatory response and serum lipopolysaccharide levels predict multiple organ failure and death in alcoholic hepatitis. <i>Hepatology</i> , 2015, 62, 762-772.	3.6	230
137	Preface. <i>Digestive Diseases</i> , 2015, 33, 1-1.	0.8	0
138	Reply to: "A cut-off serum creatinine value of 1.5 mg/dl for AKI" To be or not to be? <i>Journal of Hepatology</i> , 2015, 62, 743-744.	1.8	2
139	Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. <i>Gut</i> , 2015, 64, 531-537.	6.1	405
140	Diagnosis and management of acute kidney injury in patients with cirrhosis: Revised consensus recommendations of the International Club of Ascites. <i>Journal of Hepatology</i> , 2015, 62, 968-974.	1.8	571
141	The CLIF Consortium Acute Decompensation score (CLIF-C ADs) for prognosis of hospitalised cirrhotic patients without acute-on-chronic liver failure. <i>Journal of Hepatology</i> , 2015, 62, 831-840.	1.8	289
142	Challenges and Management of Liver Cirrhosis: Pathophysiology of Renal Dysfunction in Cirrhosis. <i>Digestive Diseases</i> , 2015, 33, 534-538.	0.8	20
143	Acute-on-chronic liver failure: A new syndrome that will re-classify cirrhosis. <i>Journal of Hepatology</i> , 2015, 62, S131-S143.	1.8	358
144	Hepatorenal syndrome: The last pieces of the puzzle or not yet?. <i>Hepatology</i> , 2015, 62, 352-354.	3.6	2

#	ARTICLE	IF	CITATIONS
145	Severe acute kidney injury associated with non-steroidal anti-inflammatory drugs in cirrhosis: A case-control study. <i>Journal of Hepatology</i> , 2015, 63, 593-600.	1.8	53
146	Transient increase in urine protein excretion during treatment with terlipressin and albumin for type-1 hepatorenal syndrome. <i>Journal of Hepatology</i> , 2015, 62, 493-495.	1.8	1
147	Acute kidney injury and acute-on-chronic liver failure classifications in prognosis assessment of patients with acute decompensation of cirrhosis. <i>Gut</i> , 2015, 64, 1616-1622.	6.1	86
148	Hyponatremia influences the outcome of patients with acute-on-chronic liver failure: an analysis of the CANONIC study. <i>Critical Care</i> , 2014, 18, 700.	2.5	41
149	Type-1 hepatorenal syndrome associated with infections in cirrhosis: Natural history, outcome of kidney function, and survival. <i>Hepatology</i> , 2014, 59, 1505-1513.	3.6	68
150	Characteristics, risk factors, and mortality of cirrhotic patients hospitalized for hepatic encephalopathy with and without acute-on-chronic liver failure (ACLF). <i>Journal of Hepatology</i> , 2014, 60, 275-281.	1.8	259
151	Bacterial infections in cirrhosis: A position statement based on the EASL Special Conference 2013. <i>Journal of Hepatology</i> , 2014, 60, 1310-1324.	1.8	685
152	Terlipressin and albumin for type-1 hepatorenal syndrome associated with sepsis. <i>Journal of Hepatology</i> , 2014, 60, 955-961.	1.8	100
153	CCL20 mediates lipopolysaccharide induced liver injury and is a potential driver of inflammation and fibrosis in alcoholic hepatitis. <i>Gut</i> , 2014, 63, 1782-1792.	6.1	118
154	Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure. <i>Journal of Hepatology</i> , 2014, 61, 1038-1047.	1.8	741
155	From Refractory Ascites to Dilutional Hyponatremia and Hepatorenal Syndrome: Current Options for Treatment. <i>Current Hepatology Reports</i> , 2014, 13, 189-197.	0.4	1
156	The biliary epithelium gives rise to liver progenitor cells. <i>Hepatology</i> , 2014, 60, 1367-1377.	3.6	158
157	A Histologic Scoring System for Prognosis of Patients With Alcoholic Hepatitis. <i>Gastroenterology</i> , 2014, 146, 1231-1239.e6.	0.6	353
158	Reply to: "To close the stable door before the horse has bolted". <i>Journal of Hepatology</i> , 2014, 60, 679-680.	1.8	0
159	Chronic kidney disease: A major concern in liver transplantation in the XXI century. <i>Journal of Hepatology</i> , 2014, 61, 196-197.	1.8	7
160	Urinary neutrophil gelatinase-associated lipocalin predicts kidney outcome and death in patients with cirrhosis and bacterial infections. <i>Journal of Hepatology</i> , 2014, 61, 35-42.	1.8	98
161	Toward an Improved Definition of Acute-on-Chronic Liver Failure. <i>Gastroenterology</i> , 2014, 147, 4-10.	0.6	255
162	Satavaptan treatment for ascites in patients with cirrhosis: a meta-analysis of effect on hepatic encephalopathy development. <i>Metabolic Brain Disease</i> , 2013, 28, 301-305.	1.4	26

#	ARTICLE	IF	CITATIONS
163	Hyponatremia in Cirrhosis: Evaluation and Treatment. , 2013, , 145-157.		1
164	Effects of intravenous albumin in patients with cirrhosis and episodic hepatic encephalopathy: A randomized double-blind study. Journal of Hepatology, 2013, 59, 1184-1192.	1.8	102
165	Relative adrenal insufficiency in decompensated cirrhosis: Relationship to short-term risk of severe sepsis, hepatorenal syndrome, and death. Hepatology, 2013, 58, 1757-1765.	3.6	120
166	A modified acute kidney injury classification for diagnosis and risk stratification of impairment of kidney function in cirrhosis. Journal of Hepatology, 2013, 59, 474-481.	1.8	249
167	Current treatment strategies for hepatorenal syndrome. Clinical Liver Disease, 2013, 2, 136-139.	1.0	2
168	Transcriptome analysis identifies TNF superfamily receptors as potential therapeutic targets in alcoholic hepatitis. Gut, 2013, 62, 452-460.	6.1	167
169	Reply to: "Effect of albumin on survival in septic cirrhotic patients other than spontaneous bacterial peritonitis. The question remains open" Journal of Hepatology, 2013, 58, 640.	1.8	4
170	Reply to: "Acute-on-chronic liver failure" Its definition remains unclear" Journal of Hepatology, 2013, 59, 191.	1.8	2
171	Acute-on-Chronic Liver Failure Is a Distinct Syndrome That Develops in Patients With Acute Decompensation of Cirrhosis. Gastroenterology, 2013, 144, 1426-1437.e9.	0.6	2,211
172	LEFT ventricular function assessed by echocardiography in cirrhosis: Relationship to systemic hemodynamics and renal dysfunction. Journal of Hepatology, 2013, 58, 51-57.	1.8	129
173	Albumin: Pathophysiologic basis of its role in the treatment of cirrhosis and its complications. Hepatology, 2013, 58, 1836-1846.	3.6	327
174	Results of pretransplant treatment of hepatorenal syndrome with terlipressin. Current Opinion in Organ Transplantation, 2013, 18, 265-270.	0.8	10
175	Renal failure in cirrhosis: prerenal azotemia, hepatorenal syndrome and acute tubular necrosis. Nephrology Dialysis Transplantation, 2012, 27, 2625-2628.	0.4	37
176	Satavaptan for the management of ascites in cirrhosis: efficacy and safety across the spectrum of ascites severity. Gut, 2012, 61, 108-116.	6.1	121
177	Management of critically-ill cirrhotic patients. Journal of Hepatology, 2012, 56, S13-S24.	1.8	113
178	Acute Kidney Injury Is an Early Predictor of Mortality for Patients With Alcoholic Hepatitis. Clinical Gastroenterology and Hepatology, 2012, 10, 65-71.e3.	2.4	155
179	Tolvaptan, an oral vasopressin antagonist, in the treatment of hyponatremia in cirrhosis. Journal of Hepatology, 2012, 56, 571-578.	1.8	115
180	Renal failure and hyponatremia in patients with cirrhosis and skin and soft tissue infection. A retrospective study. Journal of Hepatology, 2012, 56, 1040-1046.	1.8	50

#	ARTICLE	IF	CITATIONS
181	Urinary neutrophil gelatinase-associated lipocalin as biomarker in the differential diagnosis of impairment of kidney function in cirrhosis. <i>Journal of Hepatology</i> , 2012, 57, 267-273.	1.8	191
182	Reply to: "Encephalopathy or hepatic encephalopathy?" <i>Journal of Hepatology</i> , 2012, 57, 929-930.	1.8	0
183	Albumin for bacterial infections other than spontaneous bacterial peritonitis in cirrhosis. A randomized, controlled study. <i>Journal of Hepatology</i> , 2012, 57, 759-765.	1.8	179
184	Hepatorenal syndrome, MELD score and liver transplantation: An evolving issue with relevant implications for clinical practice. <i>Journal of Hepatology</i> , 2012, 57, 1135-1140.	1.8	87
185	Effects of Fractionated Plasma Separation and Adsorption on Survival in Patients With Acute-on-Chronic Liver Failure. <i>Gastroenterology</i> , 2012, 142, 782-789.e3.	0.6	355
186	Effects of pentoxifylline on intestinal bacterial overgrowth, bacterial translocation and spontaneous bacterial peritonitis in cirrhotic rats with ascites. <i>Digestive and Liver Disease</i> , 2012, 44, 239-244.	0.4	17
187	Factors related to quality of life in patients with cirrhosis and ascites: Relevance of serum sodium concentration and leg edema. <i>Journal of Hepatology</i> , 2012, 57, 1199-1206.	1.8	116
188	Acute-on chronic liver failure. <i>Journal of Hepatology</i> , 2012, 57, 1336-1348.	1.8	545
189	Hepatic hemodynamics and transient elastography in alcoholic foamy degeneration: report of 2 cases. <i>Annals of Hepatology</i> , 2012, 11, 399-403.	0.6	10
190	Prevalence and risk factors of infections by multiresistant bacteria in cirrhosis: A prospective study. <i>Hepatology</i> , 2012, 55, 1551-1561.	3.6	498
191	Liver progenitor cell markers correlate with liver damage and predict short-term mortality in patients with alcoholic hepatitis. <i>Hepatology</i> , 2012, 55, 1931-1941.	3.6	177
192	Hepatorenal Syndrome: A Severe, but Treatable, Cause of Kidney Failure in Cirrhosis. <i>American Journal of Kidney Diseases</i> , 2012, 59, 874-885.	2.1	58
193	Terlipressin for Hepatorenal Syndrome: Predictors of Response. <i>Frontiers of Gastrointestinal Research</i> , 2011, , 172-177.	0.1	1
194	Prognostic Importance of the Cause of Renal Failure in Patients With Cirrhosis. <i>Gastroenterology</i> , 2011, 140, 488-496.e4.	0.6	311
195	Management of patients with cirrhosis awaiting liver transplantation. <i>Gut</i> , 2011, 60, 412-421.	6.1	64
196	The Amount of Alcohol Consumption Negatively Impacts Short-Term Mortality in Mexican Patients With Alcoholic Hepatitis. <i>American Journal of Gastroenterology</i> , 2011, 106, 1472-1480.	0.2	33
197	Cerebral magnetic resonance imaging reveals marked abnormalities of brain tissue density in patients with cirrhosis without overt hepatic encephalopathy. <i>Journal of Hepatology</i> , 2011, 55, 564-573.	1.8	96
198	Pharmacological management of hepatorenal syndrome: Lessons from non-responders. <i>Journal of Hepatology</i> , 2011, 55, 268-269.	1.8	17

#	ARTICLE	IF	CITATIONS
199	Acute-on-chronic liver failure: the kidneys. <i>Current Opinion in Critical Care</i> , 2011, 17, 184-189.	1.6	38
200	Hepatorenal syndrome, pharmacological therapy, and liver transplantation. <i>Liver Transplantation</i> , 2011, 17, 1244-1246.	1.3	11
201	Renal Dysfunction and Pathogenesis and Treatment of Ascites and Hepatorenal Syndrome in Cirrhosis. , 2011, , 102-112.		1
202	Predictors of response to therapy with terlipressin and albumin in patients with cirrhosis and type 1 hepatorenal syndrome. <i>Hepatology</i> , 2010, 51, 219-226.	3.6	211
203	Reduction of advanced liver fibrosis by short-term targeted delivery of an angiotensin receptor blocker to hepatic stellate cells in rats. <i>Hepatology</i> , 2010, 51, NA-NA.	3.6	96
204	Chrelin attenuates hepatocellular injury and liver fibrogenesis in rodents and influences fibrosis progression in humans. <i>Hepatology</i> , 2010, 51, 974-985.	3.6	141
205	Cigarette smoking exacerbates nonalcoholic fatty liver disease in obese rats. <i>Hepatology</i> , 2010, 51, 1567-1576.	3.6	117
206	Hyponatremia in patients treated with terlipressin for severe gastrointestinal bleeding due to portal hypertension. <i>Hepatology</i> , 2010, 52, 1783-1790.	3.6	88
207	Hepatocarcinoma cells stimulate the growth, migration and expression of pro-angiogenic genes in human hepatic stellate cells. <i>Liver International</i> , 2010, 30, 31-41.	1.9	44
208	Risk factors for hepatic encephalopathy in patients with cirrhosis and refractory ascites: relevance of serum sodium concentration. <i>Liver International</i> , 2010, 30, 1137-1142.	1.9	87
209	Effects of a selective vasopressin V2 receptor antagonist, satavaptan, on ascites recurrence after paracentesis in patients with cirrhosis. <i>Journal of Hepatology</i> , 2010, 53, 283-290.	1.8	78
210	Renal and circulatory dysfunction in cirrhosis: Current management and future perspectives. <i>Journal of Hepatology</i> , 2010, 53, 1135-1145.	1.8	97
211	Diuretic agents for ascites: joining forces from the start?. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2010, 7, 310-311.	8.2	1
212	Effects of losartan on hepatic expression of nonphagocytic NADPH oxidase and fibrogenic genes in patients with chronic hepatitis C. <i>American Journal of Physiology - Renal Physiology</i> , 2009, 297, G726-G734.	1.6	110
213	Clinically relevant differences in the model for end-stage liver disease and model for end-stage liver disease-sodium scores determined at three university-based laboratories of the same area. <i>Liver Transplantation</i> , 2009, 15, 300-305.	1.3	18
214	Report of the first international liver transplantation society expert panel consensus conference on renal insufficiency in liver transplantation. <i>Liver Transplantation</i> , 2009, 15, S1-S34.	1.3	135
215	Is albumin infusion necessary after large volume paracentesis? Pro " main arguments. <i>Liver International</i> , 2009, 29, 636-638.	1.9	23
216	Antiphospholipid syndrome during pegylated interferon alpha-2a therapy for chronic hepatitis C. <i>Digestive and Liver Disease</i> , 2009, 41, e4-e7.	0.4	14

#	ARTICLE	IF	CITATIONS
217	Hepatic Expression of CXC Chemokines Predicts Portal Hypertension and Survival in Patients With Alcoholic Hepatitis. <i>Gastroenterology</i> , 2009, 136, 1639-1650.	0.6	197
218	Hyponatremia Is a Risk Factor of Hepatic Encephalopathy in Patients With Cirrhosis: A Prospective Study With Time-Dependent Analysis. <i>American Journal of Gastroenterology</i> , 2009, 104, 1382-1389.	0.2	206
219	Renal Failure in Cirrhosis. <i>New England Journal of Medicine</i> , 2009, 361, 1279-1290.	13.9	713
220	Atorvastatin attenuates angiotensin II-induced inflammatory actions in the liver. <i>American Journal of Physiology - Renal Physiology</i> , 2009, 296, G147-G156.	1.6	79
221	A Patient With Cirrhosis and Increasing Creatinine Level: What Is It and What to Do?. <i>Clinical Gastroenterology and Hepatology</i> , 2009, 7, 1287-1291.	2.4	3
222	Portal hypertension. <i>Current Opinion in Gastroenterology</i> , 2009, 25, 195-201.	1.0	34
223	What's new in the treatment of ascites and spontaneous bacterial peritonitis. <i>Current Gastroenterology Reports</i> , 2008, 10, 7-14.	1.1	9
224	Effects of sataavaptan, a selective vasopressin V ₂ receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: A randomized trial. <i>Hepatology</i> , 2008, 48, 204-213.	3.6	183
225	Hyponatremia in cirrhosis: Pathogenesis, clinical significance, and management. <i>Hepatology</i> , 2008, 48, 1002-1010.	3.6	267
226	Terlipressin and Albumin vs Albumin in Patients With Cirrhosis and Hepatorenal Syndrome: A Randomized Study. <i>Gastroenterology</i> , 2008, 134, 1352-1359.	0.6	541
227	Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. <i>Postgraduate Medical Journal</i> , 2008, 84, 662-670.	0.9	504
228	A New Scoring System for Prognostic Stratification of Patients With Alcoholic Hepatitis. <i>American Journal of Gastroenterology</i> , 2008, 103, 2747-2756.	0.2	268
229	Predicting Mortality in Cirrhosis – Serum Sodium Helps. <i>New England Journal of Medicine</i> , 2008, 359, 1060-1062.	13.9	39
230	The Management of Ascites and Hyponatremia in Cirrhosis. <i>Seminars in Liver Disease</i> , 2008, 28, 043-058.	1.8	79
231	Pathogenesis and Treatment of Hepatorenal Syndrome. <i>Seminars in Liver Disease</i> , 2008, 28, 081-095.	1.8	171
232	Complications of Cirrhosis. <i>Seminars in Liver Disease</i> , 2008, 28, 001-001.	1.8	2
233	MELD score and serum sodium in the prediction of survival of patients with cirrhosis awaiting liver transplantation. <i>Gut</i> , 2007, 56, 1283-1290.	6.1	180
234	Advances in the pathogenesis and treatment of type-1 and type-2 hepatorenal syndrome. <i>Journal of Hepatology</i> , 2007, 46, 935-946.	1.8	135

#	ARTICLE	IF	CITATIONS
235	Vaptans: A promising therapy in the management of advanced cirrhosis. <i>Journal of Hepatology</i> , 2007, 46, 1150-1152.	1.8	26
236	Hepatic Expression of Candidate Genes in Patients With Alcoholic Hepatitis: Correlation With Disease Severity. <i>Gastroenterology</i> , 2007, 132, 687-697.	0.6	108
237	Primary Prophylaxis of Spontaneous Bacterial Peritonitis Delays Hepatorenal Syndrome and Improves Survival in Cirrhosis. <i>Gastroenterology</i> , 2007, 133, 818-824.	0.6	639
238	Bradykinin Attenuates Hepatocellular Damage and Fibrosis in Rats With Chronic Liver Injury. <i>Gastroenterology</i> , 2007, 133, 2019-2028.	0.6	41
239	Therapy with vasoconstrictor drugs in cirrhosis: The time has arrived. <i>Hepatology</i> , 2007, 46, 1685-1687.	3.6	12
240	Hepatic stellate cell activation in liver transplant patients with hepatitis C recurrence and in non-transplanted patients with chronic hepatitis C. <i>Liver Transplantation</i> , 2007, 13, 1017-1027.	1.3	24
241	Liver Transplant Using Donors After Unexpected Cardiac Death: Novel Preservation Protocol and Acceptance Criteria. <i>American Journal of Transplantation</i> , 2007, 7, 1849-1855.	2.6	279
242	Resistin as an Intrahepatic Cytokine. <i>American Journal of Pathology</i> , 2006, 169, 2042-2053.	1.9	142
243	Hepatorenal Syndrome. <i>Clinics in Liver Disease</i> , 2006, 10, 371-385.	1.0	16
244	Hyponatremia Impairs Early Posttransplantation Outcome in Patients With Cirrhosis Undergoing Liver Transplantation. <i>Gastroenterology</i> , 2006, 130, 1135-1143.	0.6	179
245	Hyponatremia in cirrhosis: clinical features and management. <i>Gastroenterologie Clinique Et Biologique</i> , 2006, 30, 1144-1151.	0.9	20
246	Adrenal insufficiency in patients with cirrhosis and septic shock: Effect of treatment with hydrocortisone on survival. <i>Hepatology</i> , 2006, 44, 1288-1295.	3.6	279
247	Hyponatremia in cirrhosis: Results of a patient population survey. <i>Hepatology</i> , 2006, 44, 1535-1542.	3.6	349
248	Aquaporin-1 and aquaporin-2 urinary excretion in cirrhosis: Relationship with ascites and hepatorenal syndrome. <i>Hepatology</i> , 2006, 44, 1555-1563.	3.6	49
249	New Treatments of Hepatorenal Syndrome. <i>Seminars in Liver Disease</i> , 2006, 26, 254-264.	1.8	33
250	Norepinephrine induces calcium spikes and proinflammatory actions in human hepatic stellate cells. <i>American Journal of Physiology - Renal Physiology</i> , 2006, 291, G877-G884.	1.6	54
251	Therapy Insight: management of hepatorenal syndrome. <i>Nature Reviews Gastroenterology & Hepatology</i> , 2006, 3, 338-348.	1.7	22
252	Effects of celecoxib and naproxen on renal function in nonazotemic patients with cirrhosis and ascites. <i>Hepatology</i> , 2005, 41, 579-587.	3.6	79

#	ARTICLE	IF	CITATIONS
253	MELD score and clinical type predict prognosis in hepatorenal syndrome: Relevance to liver transplantation. <i>Hepatology</i> , 2005, 41, 1282-1289.	3.6	338
254	Circulatory function and hepatorenal syndrome in cirrhosis. <i>Hepatology</i> , 2005, 42, 439-447.	3.6	537
255	Management of Refractory Ascites. <i>Clinical Gastroenterology and Hepatology</i> , 2005, 3, 1187-1191.	2.4	32
256	Management of complications of cirrhosis in patients awaiting liver transplantation. <i>Journal of Hepatology</i> , 2005, 42, S124-S133.	1.8	56
257	Attenuated hepatic inflammation and fibrosis in angiotensin type 1a receptor deficient mice. <i>Journal of Hepatology</i> , 2005, 43, 317-323.	1.8	105
258	Genomic and functional characterization of stellate cells isolated from human cirrhotic livers. <i>Journal of Hepatology</i> , 2005, 43, 272-282.	1.8	78
259	Renal Failure in Patients With Cirrhosis and Sepsis Unrelated to Spontaneous Bacterial Peritonitis: Value of MELD Score. <i>Gastroenterology</i> , 2005, 129, 1944-1953.	0.6	232
260	Liver Fibrogenesis: A New Role for the Renin-Angiotensin System. <i>Antioxidants and Redox Signaling</i> , 2005, 7, 1346-1355.	2.5	141
261	Mechanisms of Sodium Retention, Ascites Formation, and Renal Dysfunction in Cirrhosis. , 2005, , 65-84.		3
262	Increased vascular heme oxygenase-1 expression contributes to arterial vasodilation in experimental cirrhosis in rats. <i>Hepatology</i> , 2004, 39, 1075-1087.	3.6	62
263	Effects of dilutional hyponatremia on brain organic osmolytes and water content in patients with cirrhosis. <i>Hepatology</i> , 2004, 39, 1613-1622.	3.6	87
264	Management of hepatorenal syndrome: Another piece of the puzzle. <i>Hepatology</i> , 2004, 40, 16-18.	3.6	19
265	Effects of contrast media on renal function in patients with cirrhosis: A prospective study. <i>Hepatology</i> , 2004, 40, 646-651.	3.6	61
266	Contrast medium-associated renal dysfunction in patients with cirrhosis. <i>Hepatology</i> , 2004, 40, 1474-1474.	3.6	3
267	Management of Cirrhosis and Ascites. <i>New England Journal of Medicine</i> , 2004, 350, 1646-1654.	13.9	721
268	Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome. A case-control study. <i>Journal of Hepatology</i> , 2004, 40, 140-146.	1.8	203
269	Goodbye from Barcelona!. <i>Journal of Hepatology</i> , 2004, 41, 893-895.	1.8	1
270	Increased carbon monoxide production in patients with cirrhosis with and without spontaneous bacterial peritonitis. <i>Hepatology</i> , 2003, 38, 452-459.	3.6	73

#	ARTICLE	IF	CITATIONS
271	The management of ascites in cirrhosis: Report on the consensus conference of the International Ascites Club. <i>Hepatology</i> , 2003, 38, 258-266.	3.6	744
272	Human hepatic stellate cells show features of antigen-presenting cells and stimulate lymphocyte proliferation. <i>Hepatology</i> , 2003, 38, 919-929.	3.6	186
273	Activated human hepatic stellate cells express the renin-angiotensin system and synthesize angiotensin II. <i>Gastroenterology</i> , 2003, 125, 117-125.	0.6	317
274	Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: A randomized double-blind multicenter trial. <i>Gastroenterology</i> , 2003, 124, 933-939.	0.6	280
275	Hepatorenal syndrome. <i>Lancet, The</i> , 2003, 362, 1819-1827.	6.3	543
276	Human hepatic stellate cells show features of antigen-presenting cells and stimulate lymphocyte proliferation. <i>Hepatology</i> , 2003, 38, 919-929.	3.6	88
277	External validation of a prognostic model for predicting survival of cirrhotic patients with refractory ascites. <i>American Journal of Gastroenterology</i> , 2002, 97, 2374-2378.	0.2	27
278	Increased plasma levels of neuropeptide Y in hepatorenal syndrome. <i>Journal of Hepatology</i> , 2002, 36, 349-355.	1.8	23
279	Hepatorenal syndrome in cirrhosis: Pathogenesis and treatment. <i>Gastroenterology</i> , 2002, 122, 1658-1676.	0.6	143
280	Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. <i>Gastroenterology</i> , 2002, 123, 1839-1847.	0.6	523
281	Good news for hepatorenal syndrome. <i>Hepatology</i> , 2002, 36, 504-506.	3.6	18
282	Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: Results of a prospective, nonrandomized study. <i>Hepatology</i> , 2002, 36, 941-948.	3.6	497
283	A prognostic model for predicting survival in cirrhosis with ascites. <i>Journal of Hepatology</i> , 2001, 34, 46-52.	1.8	225
284	Human hepatic stellate cells secrete adrenomedullin: potential autocrine factor in the regulation of cell contractility. <i>Journal of Hepatology</i> , 2001, 34, 222-229.	1.8	24
285	Human myofibroblastic hepatic stellate cells express Ca ²⁺ -activated K ⁺ channels that modulate the effects of endothelin-1 and nitric oxide. <i>Journal of Hepatology</i> , 2001, 35, 739-748.	1.8	27
286	The model for end-stage liver disease (MELD) score predicts survival in patients with spontaneous bacterial peritonitis, and with ascites. <i>Gastroenterology</i> , 2001, 120, A378.	0.6	4
287	In vitro and in vivo activation of rat hepatic stellate cells results in de novo expression of L-type voltage-operated calcium channels. <i>Hepatology</i> , 2001, 33, 956-962.	3.6	57
288	Renal failure after upper gastrointestinal bleeding in cirrhosis: Incidence, clinical course, predictive factors, and short-term prognosis. <i>Hepatology</i> , 2001, 34, 671-676.	3.6	273

#	ARTICLE	IF	CITATIONS
289	Stenosis of the suprahepatic inferior vena cava as a complication of transjugular intrahepatic portosystemic shunt in Budd-Chiari patients. <i>Liver Transplantation</i> , 2001, 7, 649-651.	1.3	16
290	Diagnosis and treatment of hepatorenal syndrome. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2000, 14, 945-957.	1.0	10
291	Hepatorenal syndrome. <i>Liver Transplantation</i> , 2000, 6, S63-S71.	1.3	31
292	HEPATORENAL SYNDROME. <i>Clinics in Liver Disease</i> , 2000, 4, 487-507.	1.0	21
293	Hepatocyte-derived cysteinyl leukotrienes modulate vascular tone in experimental cirrhosis. <i>Gastroenterology</i> , 2000, 119, 794-805.	0.6	69
294	Angiotensin II induces contraction and proliferation of human hepatic stellate cells. <i>Gastroenterology</i> , 2000, 118, 1149-1156.	0.6	459
295	Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome. <i>Journal of Hepatology</i> , 2000, 33, 43-48.	1.8	381
296	Atrial natriuretic peptide antagonizes endothelin-induced calcium increase and cell contraction in cultured human hepatic stellate cells. <i>Hepatology</i> , 1999, 30, 501-509.	3.6	30
297	Ascites and liver test abnormalities during severe ovarian hyperstimulation syndrome. <i>American Journal of Gastroenterology</i> , 1999, 94, 994-999.	0.2	11
298	Effect of Intravenous Albumin on Renal Impairment and Mortality in Patients with Cirrhosis and Spontaneous Bacterial Peritonitis. <i>New England Journal of Medicine</i> , 1999, 341, 403-409.	13.9	1,519
299	Hepatorenal Syndrome. <i>Journal of the American Society of Nephrology: JASN</i> , 1999, 10, 1833-1839.	3.0	58
300	Increased renal and vascular cytosolic phospholipase A2 activity in rats with cirrhosis and ascites. <i>Hepatology</i> , 1998, 27, 42-47.	3.6	17
301	Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion. <i>Hepatology</i> , 1998, 27, 35-41.	3.6	296
302	Increased cerebrovascular resistance in cirrhotic patients with ascites. <i>Hepatology</i> , 1998, 28, 39-44.	3.6	138
303	Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: Effects on renal function and vasoactive systems. <i>Hepatology</i> , 1998, 28, 416-422.	3.6	374
304	Hyponatremia in cirrhosis: From pathogenesis to treatment. <i>Hepatology</i> , 1998, 28, 851-864.	3.6	237
305	Altered biosynthesis of leukotrienes and lipoxins and host defense disorders in patients with cirrhosis and ascites. <i>Gastroenterology</i> , 1998, 115, 147-156.	0.6	63
306	Increased adrenomedullin levels in cirrhosis: Relationship with hemodynamic abnormalities and vasoconstrictor systems. <i>Gastroenterology</i> , 1998, 114, 336-343.	0.6	103

#	ARTICLE	IF	CITATIONS
307	Contraction of human hepatic stellate cells activated in culture: A role for voltage-operated calcium channels. <i>Journal of Hepatology</i> , 1998, 29, 398-408.	1.8	54
308	Antibiotic prophylaxis for spontaneous bacterial peritonitis: how and whom?. <i>Journal of Hepatology</i> , 1998, 29, 490-494.	1.8	31
309	Nitric Oxide as a Mediator of Hemodynamic Abnormalities and Sodium and Water Retention in Cirrhosis. <i>New England Journal of Medicine</i> , 1998, 339, 533-541.	13.9	396
310	Pathophysiology of Renal Dysfunction in Cirrhosis. <i>Digestion</i> , 1998, 59, 11-15.	1.2	9
311	Hepatorenal Syndrome. <i>Seminars in Liver Disease</i> , 1997, 17, 233-247.	1.8	83
312	Pathogenesis of Ascites in Cirrhosis. <i>Seminars in Liver Disease</i> , 1997, 17, 175-189.	1.8	104
313	PATHOPHYSIOLOGY, COMPLICATIONS, AND TREATMENT OF ASCITES. <i>Clinics in Liver Disease</i> , 1997, 1, 129-155.	1.0	21
314	Practical Recommendations for the Treatment of Ascites and Its Complications. <i>Drugs</i> , 1997, 54, 571-580.	4.9	21
315	Effect of therapeutic paracentesis on plasma volume and transvascular escape rate of albumin in patients with cirrhosis. <i>Journal of Hepatology</i> , 1997, 27, 645-653.	1.8	59
316	Urinary endothelin-like immunoreactivity in patients with cirrhosis. <i>Journal of Hepatology</i> , 1997, 27, 810-816.	1.8	15
317	Diuretic requirements after therapeutic paracentesis in non-azotemic patients with cirrhosis. A randomized double-blind trials of spironolactone versus placebo. <i>Journal of Hepatology</i> , 1997, 26, 614-620.	1.8	84
318	Management of ascites in cirrhosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1997, 12, 723-733.	1.4	8
319	10 Ascites and renal functional abnormalities in cirrhosis. Pathogenesis and treatment. <i>Bailliere's Clinical Gastroenterology</i> , 1997, 11, 365-385.	0.9	18
320	TIPS and refractory ascites. Lessons from the recent history of ascites therapy. <i>Journal of Hepatology</i> , 1996, 25, 221-223.	1.8	21
321	Aquaretic agents: a new potential treatment of dilutional hyponatremia in cirrhosis. <i>Journal of Hepatology</i> , 1996, 24, 506-512.	1.8	35
322	Renal and neurohormonal changes following simultaneous administration of systemic vasoconstrictors and dopamine or prostacyclin in cirrhotic patients with hepatorenal syndrome. <i>Journal of Hepatology</i> , 1996, 25, 916-923.	1.8	57
323	Management of ascites, hepatorenal syndrome, and spontaneous bacterial peritonitis in cirrhosis. <i>Current Opinion in Gastroenterology</i> , 1995, 11, 233-237.	1.0	1
324	Treatment of patients with cirrhosis and refractory ascites using LeVeen shunt with titanium tip: Comparison with therapeutic paracentesis. <i>Hepatology</i> , 1995, 22, 124-131.	3.6	62

#	ARTICLE	IF	CITATIONS
325	Effect of upright posture and physical exercise on endogenous neurohormonal systems in cirrhotic patients with sodium retention and normal supine plasma renin, aldosterone, and norepinephrine levels. <i>Hepatology</i> , 1995, 22, 479-487.	3.6	41
326	Endothelium-dependent vascular hyporesponsiveness without detection of nitric oxide synthase induction in aortas of cirrhotic rats. <i>Hepatology</i> , 1995, 22, 1856-1862.	3.6	60
327	Normalization of nitric oxide production corrects arterial vasodilation and hyperdynamic circulation in cirrhotic rats. <i>Gastroenterology</i> , 1995, 109, 1624-1630.	0.6	165
328	Increased plasma endothelin in cirrhosis. Relationship with systemic endotoxemia and response to changes in effective blood volume. <i>Journal of Hepatology</i> , 1995, 22, 389-398.	1.8	49
329	Treatment of patients with cirrhosis and refractory ascites using LeVeen shunt with titanium tip: Comparison with therapeutic paracentesis*1. <i>Hepatology</i> , 1995, 22, 124-131.	3.6	54
330	Increased aortic cyclic guanosine monophosphate concentration in experimental cirrhosis in rats: Evidence for a role of nitric oxide in the pathogenesis of arterial vasodilation in cirrhosis*1. <i>Hepatology</i> , 1995, 21, 1625-1631.	3.6	9
331	Peripheral Arterial Vasodilation: Determinant of Functional Spectrum of Cirrhosis. <i>Seminars in Liver Disease</i> , 1994, 14, 14-22.	1.8	94
332	Effects of low-sodium diet and spironolactone on portal pressure in patients with compensated cirrhosis. <i>Hepatology</i> , 1994, 19, 1095-1099.	3.6	111
333	Impact of shunt surgery for variceal bleeding in the natural history of ascites in cirrhosis: A retrospective study. <i>Hepatology</i> , 1994, 20, 584-591.	3.6	43
334	Diagnosis of functional kidney failure of cirrhosis with Doppler sonography: Prognostic value of resistive index. <i>Hepatology</i> , 1994, 20, 839-844.	3.6	124
335	Total paracentesis with dextran 40 vs diuretics in the treatment of ascites in cirrhosis: a randomized controlled study. <i>Journal of Hepatology</i> , 1994, 20, 282-288.	1.8	80
336	Impact of shunt surgery for variceal bleeding in the natural history of ascites in cirrhosis: A retrospective study. <i>Hepatology</i> , 1994, 20, 584-591.	3.6	6
337	Effect of Dipyridamole on Kidney Function in Cirrhosis. <i>Hepatology</i> , 1993, 17, 59-64.	3.6	33
338	Spontaneous bacterial peritonitis in cirrhosis: Predictive factors of infection resolution and survival in patients treated with cefotaxime. <i>Hepatology</i> , 1993, 17, 251-257.	3.6	215
339	Brachial and femoral artery blood flow in cirrhosis: Relationship to kidney dysfunction. <i>Hepatology</i> , 1993, 17, 788-793.	3.6	136
340	Renal effects of acute isosorbide-5-mononitrate administration in cirrhosis. <i>Hepatology</i> , 1993, 17, 800-806.	3.6	63
341	Mechanism of sodium retention and ascites formation in cirrhosis. <i>Journal of Hepatology</i> , 1993, 17, S24-S28.	1.8	33
342	Paracentesis in the management of cirrhotic ascites. <i>Journal of Hepatology</i> , 1993, 17, S14-S18.	1.8	28

#	ARTICLE	IF	CITATIONS
343	Circulating levels of endothelin in cirrhosis. <i>Gastroenterology</i> , 1993, 104, 1485-1491.	0.6	198
344	Precision in nutritional diagnoses. <i>Gastroenterology</i> , 1993, 105, 1923.	0.6	1
345	Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. <i>Gastroenterology</i> , 1993, 105, 229-236.	0.6	820
346	Spontaneous bacterial peritonitis in cirrhosis: Predictive factors of infection resolution and survival in patients treated with cefotaxime. <i>Hepatology</i> , 1993, 17, 251-257.	3.6	15
347	Arteriolar vasodilation and the pathogenesis of the hyperdynamic circulation and renal sodium and water retention in cirrhosis. <i>Gastroenterology</i> , 1992, 102, 1077-1079.	0.6	37
348	Renal insensitivity to atrial natriuretic peptide in patients with cirrhosis and ascites. <i>Gastroenterology</i> , 1992, 102, 280-286.	0.6	44
349	Effects of somatostatin on renal function in cirrhosis. <i>Gastroenterology</i> , 1992, 103, 1868-1874.	0.6	54
350	Mineralocorticoid escape in patients with compensated cirrhosis and portal hypertension. <i>Gastroenterology</i> , 1992, 102, 2114-2119.	0.6	59
351	Pharmacotherapy of Ascites Associated with Cirrhosis. <i>Drugs</i> , 1992, 43, 316-332.	4.9	36
352	Assessment of the renin-angiotensin system in cirrhotic patients. <i>Journal of Hepatology</i> , 1992, 15, 179-183.	1.8	59
353	Selective intestinal decontamination in the prevention of bacterial infection in patients with acute liver failure. <i>Journal of Hepatology</i> , 1992, 14, 280-285.	1.8	63
354	Incidence and predictive factors of first episode of spontaneous bacterial peritonitis in cirrhosis with ascites: Relevance of ascitic fluid protein concentration. <i>Hepatology</i> , 1992, 16, 724-727.	3.6	204
355	TREATMENT OF ASCITES IN CIRRHOSIS. <i>Gastroenterology Clinics of North America</i> , 1992, 21, 237-256.	1.0	36
356	Molecular forms and biological activity of atrial natriuretic factor in patients with cirrhosis and ascites. <i>Hepatology</i> , 1991, 14, 601-607.	3.6	17
357	Paracentesis with Intravenous Infusion of Albumin as Compared with Peritoneovenous Shunting in Cirrhosis with Refractory Ascites. <i>New England Journal of Medicine</i> , 1991, 325, 829-835.	13.9	294
358	Total paracentesis associated with intravenous albumin management of patients with cirrhosis and ascites. <i>Gastroenterology</i> , 1990, 98, 146-151.	0.6	208
359	Dextran-70 versus albumin as plasma expanders in cirrhotic patients with tense ascites treated with total paracentesis. <i>Gastroenterology</i> , 1990, 99, 1736-1744.	0.6	179
360	Effects of intravenous amino acid infusion and dietary proteins on kidney function in cirrhosis. <i>Hepatology</i> , 1990, 11, 379-386.	3.6	19

#	ARTICLE	IF	CITATIONS
361	Natriuretic hormone activity in the urine of cirrhotic patients. <i>Hepatology</i> , 1990, 12, 467-475.	3.6	19
362	Norflaxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: Results of a double-blind, placebo-controlled trial. <i>Hepatology</i> , 1990, 12, 716-724.	3.6	587
363	Prognostic factors of hepatocellular carcinoma in the west: A multivariate analysis in 206 patients. <i>Hepatology</i> , 1990, 12, 753-760.	3.6	229
364	Prostaglandins and the treatment of hepatorenal syndrome in cirrhosis. <i>Journal of Hepatology</i> , 1990, 11, 142-144.	1.8	14
365	Natural history of hepatocellular carcinoma in Spain. <i>Journal of Hepatology</i> , 1990, 10, 311-317.	1.8	122
366	Treatment of ascites and renal failure in cirrhosis. <i>Bailliere's Clinical Gastroenterology</i> , 1989, 3, 165-186.	0.9	5
367	Recurrence of spontaneous bacterial peritonitis in cirrhosis: Frequency and predictive factors. <i>Hepatology</i> , 1988, 8, 27-31.	3.6	383
368	Atrial natriuretic factor in cirrhosis with ascites: Plasma levels, cardiac release and splanchnic extraction. <i>Hepatology</i> , 1988, 8, 636-642.	3.6	170
369	Prognostic value of arterial pressure, endogenous vasoactive systems, and renal function in cirrhotic patients admitted to the hospital for the treatment of ascites. <i>Gastroenterology</i> , 1988, 94, 482-487.	0.6	438
370	Prostaglandin precursor fatty acids in cirrhosis with ascites: Effect of linoleic acid infusion in functional renal failure. <i>Clinical Science</i> , 1988, 74, 613-619.	1.8	17
371	Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. <i>Gastroenterology</i> , 1988, 94, 1493-1502.	0.6	599
372	Comparison of paracentesis and diuretics in the treatment of cirrhotics with tense ascites. <i>Gastroenterology</i> , 1987, 93, 234-241.	0.6	463
373	Compensated cirrhosis: Natural history and prognostic factors. <i>Hepatology</i> , 1987, 7, 122-128.	3.6	972
374	Renal function abnormalities, prostaglandins, and effects of nonsteroidal anti-inflammatory drugs in cirrhosis with ascites: An overview with emphasis on pathogenesis. <i>American Journal of Medicine</i> , 1986, 81, 104-122.	0.6	132
375	Urinary excretion of 6-keto-prostaglandin F1 α , thromboxane B2 and prostaglandin E2 in cirrhosis with ascites. <i>Journal of Hepatology</i> , 1986, 3, 111-117.	1.8	105
376	Sulindac Reduces the Urinary Excretion of Prostaglandins and Impairs Renal Function in Cirrhosis with Ascites. <i>Nephron</i> , 1986, 42, 298-303.	0.9	66
377	Cefotaxime is more effective than is ampicillin-tobramycin in cirrhotics with severe infections. <i>Hepatology</i> , 1985, 5, 457-462.	3.6	299
378	PARACENTESIS VERSUS DIURETICS IN THE TREATMENT OF CIRRHOTICS WITH TENSE ASCITES. <i>Lancet</i> , The, 1985, 325, 611-612.	6.3	102

#	ARTICLE	IF	CITATIONS
379	Ascites, Hepatorenal Syndrome, and Spontaneous Bacterial Peritonitis. , 0, , 487-503.		1
380	The Systemic Circulation in Cirrhosis. , 0, , 137-155.		16
381	Medical Treatment of Ascites in Cirrhosis. , 0, , 227-240.		6
382	Prognosis of Patients with Cirrhosis and Ascites. , 0, , 260-270.		36
383	Liver Transplantation for Patients with Cirrhosis and Ascites. , 0, , 271-285.		5
384	Hepatorenal Syndrome in Cirrhosis: Clinical Features, Diagnosis, and Management. , 0, , 341-359.		3
385	The Sympathetic Nervous System in Cirrhosis. , 0, , 54-72.		7
386	Atrial Natriuretic Peptide and Other Natriuretic Factors in Cirrhosis. , 0, , 73-83.		2
387	Nitric Oxide and Systemic and Renal Hemodynamic Disturbances in Cirrhosis. , 0, , 105-114.		1
388	Management of ascites and spontaneous bacterial peritonitis. , 0, , 194-209.		0
389	Extracellular Fluid Volume Homeostasis. , 0, , 1-14.		0
390	Management of Ascites and Spontaneous Bacterial Peritonitis. , 0, , 158-167.		0